Evaluation of spondylarthritis activity by patients and physicians: ASDAS, BASDAI, PASS, and flares in 200 patients

Joint Bone Spine

Volumn 80, Issue 4, 2013, Pages 393-398

  Godfrin Valnet, Marie ^a   Prati, Clément ^a   Puyraveau, Marc ^b   Toussirot, Eric ^a   Letho Gyselink, Hélène ^a   Wendling, Daniel ^a  

^a UNIVERSITÉ DE FRANCHE COMTÉ   (France)

^b HÔPITAL SAINT JACQUES   (France)

Author keywords

ASDAS; BASDAI; Disease activity cutoffs; Flare; PASS; Patient reported outcomes; Spondylarthritis

Indexed keywords

C REACTIVE PROTEIN;

ADULT; ANKYLOSING SPONDYLITIS DISEASE ACTIVITY SCORE; ARTICLE; BATH ANKYLOSING SPONDYLITIS DISEASE ACTIVITY INDEX; BATH ANKYLOSING SPONDYLITIS FUNCTIONAL INDEX; BECK DEPRESSION INVENTORY; DEPRESSION; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; FOLLOW UP; FRANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PATIENT ACCEPTABLE SYMPTOM STATE; PROSPECTIVE STUDY; REMISSION; SPONDYLARTHRITIS; VISUAL ANALOG SCALE;

EID: 84880332367     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2013.01.003     Document Type: Article

References (35)

1. Braun J., Van der Berg R., Baraliakos X., et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2011, 70:896-904.
2. Zochling J., Braun J. Remission in ankylosing spondylitis. Clin Exp Rheumatol 2006, 24:88-92.
3. Garret S., Jenkinson T., Kennedy L.G., et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994, 21:2286-2291.
4. Calin A., Garrett S., Whitelock H., et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994, 21:2281-2285.
5. Lukas C. Composite criteria for disease activity measurement in spondylarthropathies. Rev Rhum Monographies 2010, 77:48-51.
6. Machado P., Van der Heidje D. How to measure disease activity in axial spondyloarthritis?. Curr Opin Rheumatol 2011, 23:339-345.
7. Lukas C., Landewé R., Sieper J., et al. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis 2009, 68:18-24.
8. Machado P., Landewé R., van der Heidje D. Endorsement of definitions of disease activity states and improvement scores for the ankylosing spondylitis disease activity score: results from OMERACT 10. J Rheumatol 2011, 38:1502-1506.
9. Machado P., Landewé R., Lie E., et al. Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis 2011, 70:47-53.
10. Kiltz U., Van der Heijde D., Mielants H., et al. ASAS/EULAR recommendations for the management of ankylosing spondylitis: the patient version. Ann Rheum Dis 2009, 68:1381-1386.
11. Tubach F., Pham T., Skomsvoll J., et al. Stability of the Patient Acceptable Symptomatic State over time in outcome criteria in ankylosing spondylitis. Arthritis Rheum 2006, 55:960-963.
12. Aalto A., Elovainio M., Kivimaki M., et al. The Beck Depression Inventory and General Health Questionnaire as measures of depression in the general population: a validation study using the Composite International Diagnostic Interview as the gold standard. Psychiatry Res 2012, 197:163-171.
13. Rudwaleit M., Van Der Heidje D., Landewé R., et al. The development of Assessment of Spondyloarthritis International Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 2009, 68:777-783.
14. Rudwaleit M., Van der Heidje D., Landewé R., et al. The assessment of spondyloarthritis international society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis 2011, 70:1-3.
15. Berthelot J.M., Tortellier L., Lavy-Bregeon D., et al. Large weekly variations of BASDAI and BASFI scores: usefulness of several assessments before initiations or withdrawal of anti-TNF drugs in spondylarthropathies?. Joint Bone Spine 2008, 75:245-249.
16. Ariza-ariza R., Hernandez-Cruz B., Navarro-Sarabia F. Physical function and health-related quality of life of Spanish patients with ankylosing spondylitis. Arthritis Rheum 2003, 49:483-487.
17. Mengshoel A. Life strain-related tiredness and illness-related fatigue in individuals with ankylosing spondylitis. Arthritis Care Res 2010, 62:1272-1277.
18. Da Costa D., Dritsa M., Ring A., et al. Mental health status and leisure-time physical activity contribute to fatigue intensity in patients with spondylarthropathy. Arthritis Rheum 2004, 51:1004-1008.
19. Martindale J., Smith J., Sutton C., et al. Disease and psychological status in ankylosing spondylitis. Rheumatology 2006, 45:1288-1293.
20. Maksymowych W., Richardson R., Mallon C., et al. Evaluation and validation of the Patient Acceptable Symptom State (PASS) in patients with ankylosing spondylitis. Arthritis Rheum 2007, 57:133-139.
21. Wariaghli G., Allali F., Idrissi Z., et al. Evaluation and stability of the Patient Acceptable Symptom State (PASS) over time in patients with ankylosing spondylitis. Clin Exp Rheum 2012, 30:106-109.
22. Dougados M., Luo M., Maksymowych W., et al. Evaluation of the Patient Acceptable Symptom State as an outcome measure in patients with ankylosing spondylitis: data from a randomized controlled trial. Arthritis Rheum 2008, 59:553-560.
23. Spoorenberg A., Van Tubergen A., Landewe R., et al. Measuring disease activity in ankylosing spondylitis: patient and physician have different perspectives. Rheumatology 2005, 44:789-795.
24. Van Der Heidje D., Salonen D., Weissman B.N., et al. Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up 2years. Arthritis Res Ther 2009, 11:R127.
25. Lekpa F., Farrenq V., Claudepierre P. Response criteria in spondylarthropathies: definition of a responder. Rev Rhum Monographies 2010, 77:52-58.
26. Pedersen S., Sorensen I., Hermann K., et al. Responsiveness of the Ankylosing Spondylitis Disease Activity Score (ASDAS) and clinical and MRI measures of disease activity in a 1-year follow-up study of patients with axial spondyloarthritis treated with tumor necrosis factor alpha inhibitors. Ann Rheum Dis 2010, 69:1065-1071.
27. Aydin S.Z., Can M., Atagunduz P., et al. Active disease requiring TNF-alpha-antagonist therapy can be well discriminated with different ASDAS sets: a prospective, follow-up of disease activity assessment in ankylosing spondylitis. Clin Exp Rheumatol 2010, 28:752-755.
28. Poddubnyy D.A., Rudwaleit M., Listing J., et al. Comparison of a high sensitivity and standardC reactive protein measurement in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis. Ann Rheum Dis 2010, 69:1338-1341.
29. Pedersen S., Sorensen I., Garnero P., et al. ASDAS, BASDAI and different treatment responses and their relation to biomarkers of inflammation, cartilage and bone turnover in patients with axial spondyloarthritis treated with TNFa inhibitors. Ann Rheum Dis 2001, 70:1375-1381.
30. Cooksey R., Brophy S., Gravenor M., et al. Frequency and characteristics of disease flares in ankylosing spondylitis. Rheumatology 2010, 49:929-932.
31. Brophy S., Calin A. Definition of disease flare in ankylosing spondylitis: the patients' perspective. J Rheumatol 2002, 29:954-958.
32. Stone M.A., Pomeroy E., Keat A., et al. Assessment of the impact of flares in ankylosing spondylitis disease activity using the Flare Illustration. Rheumatology 2008, 47:1213-1218.
33. Anderson J.J., Baron G., Van der Heidje D., et al. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001, 44:1876-1886.
34. Sieper J. How to define remission in ankylosing spondylitis?. Ann Rheum Dis 2012, 71:93-95.
35. Van der Heijde D., Lie E., Kvien T., et al. The ASDAS is a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis 2009, 68:1811-1818.